Biotech · Private company
AskBio Inc
Track this companyFree. Adds AskBio Inc to your Dealase workspace and tells you when its record changes.
Clinical trials107 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- AAV2-GDNF gene therapyPhase 2 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AB-1002Phase 2 · Congestive Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
- AB-1003 dose level 1Phase 2 · Limb Girdle Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- AB-1003 dose level 2Phase 2 · Limb Girdle Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- AB-1005Phase 2 · PARKINSON DISEASE (Disorder)ClinicalTrials.gov · fetched Nov 12, 2026
- AB-1009 (GAA Gene)Phase 2 · Pompe Disease (Late-onset)ClinicalTrials.gov · fetched Nov 12, 2026
- control surgeryPhase 2 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Prescriptive Infusion AlgorithmPhase 2 · PARKINSON DISEASE (Disorder)ClinicalTrials.gov · fetched Nov 12, 2026
- 3 x 10e13vg AB-1002Phase 1 · Congestive Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
- ACTUS-101Phase 1 · Pompe DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ObservationParkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- This is an observational study.Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)PHASE2 · NOT_YET_RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07215403 · fetched Nov 12, 2026
- A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)PHASE1_PHASE2 · RECRUITING · started Apr 15, 2026ClinicalTrials.gov NCT07282847 · fetched Nov 12, 2026
- AB-1005 Long-Term Follow-up StudyENROLLING_BY_INVITATION · started Sep 4, 2025ClinicalTrials.gov NCT07081841 · fetched Nov 12, 2026
- A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 11, 2024ClinicalTrials.gov NCT06285643 · fetched Nov 12, 2026
- Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart FailurePHASE2 · ACTIVE_NOT_RECRUITING · started Oct 20, 2023ClinicalTrials.gov NCT05598333 · fetched Nov 12, 2026
- A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 15, 2023ClinicalTrials.gov NCT05230459 · fetched Nov 12, 2026
- Pre-Gene Therapy Study in Parkinson's Disease and Multiple System AtrophyCOMPLETED · started Sep 29, 2022ClinicalTrials.gov NCT05699460 · fetched Nov 12, 2026
- GDNF Gene Therapy for Parkinson's DiseasePHASE1 · ACTIVE_NOT_RECRUITING · started Apr 1, 2020ClinicalTrials.gov NCT04167540 · fetched Nov 12, 2026
- AB-1002 in Patients With Class III Heart FailurePHASE1 · COMPLETED · started Nov 20, 2019ClinicalTrials.gov NCT04179643 · fetched Nov 12, 2026
- AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe DiseasePHASE1 · COMPLETED · started Dec 17, 2018ClinicalTrials.gov NCT03533673 · fetched Nov 12, 2026